Healthcare Industry News: bifurcated stent
News Release - August 11, 2009
LeMaitre Vascular Announces Extension of Endologix Powerlink Distribution
BURLINGTON, Mass., Aug. 11, 2009 -- (Healthcare Sales & Marketing Network) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT ), a provider of peripheral vascular devices and implants, today announced that is has extended its exclusive distribution of the Endologix Powerlink(r) System in twelve European countries through June 30, 2013."Since 2007 when LeMaitre Vascular began offering the Powerlink System, this bifurcated stent graft has proven to be a complimentary addition to our TAArget thoracic and UniFit abdominal endografts in Europe," said George W. LeMaitre, Chairman and CEO. "We are excited to continue offering this product line to our customers."
LeMaitre Vascular currently distributes the Powerlink System in twelve European countries, including Germany, France and the United Kingdom, among others. Distribution had previously been set to expire on December 31, 2010.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of vascular surgeons. The Company's devices are used to treat peripheral vascular disease; a condition that the Company estimates affects more than 20 million people worldwide. For more information about the Company, please visit http://www.lemaitre.com.
Forward-Looking Statements
Certain statements set forth above that are not clearly historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the Company believes that such statements are based on reasonable assumptions within the bounds of its knowledge, these forward-looking statements are neither promises nor guarantees. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include, but are not limited to, the risk of a disruption in the supply of products from Endologix, the risk that the Company's relationship with Endologix becomes impaired, and the risks and uncertainties included under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. The forward-looking statements made in this release are made only as of the date hereof, and the Company disclaims any intention or responsibility for updating predictions or expectations contained in this release.
Source: LeMaitre Vascular
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
